FMO co-invests in Moroccan pharma company
Dutch development finance institution FMO has signed a €15 million co-investment in Laprophan alongside the Mediterrania Capital IV fund, together with DEG and Proparco.
Laprophan is active in the manufacturing, distribution, import, and export of pharmaceutical products in Morocco.
FMO’s support will go to improving environmental and social practices. Overall, the transaction contributes to sustainable economic growth and supports the continued availability of locally-produced reasonably priced pharmaceuticals for the local population.